Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 1.00 |
| ▸ | HSP90AB1 | P08238 | 11/20 | 1.00 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1985679 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL1351184 | 0.95 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL29352985 | 0.95 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL12465624 | 0.95 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL1351190 | 0.95 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL1986909 | 0.90 | HSP90AA1 (0.88) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL1988577 | 0.90 | HSP90AA1 (0.88) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL1984737 | 0.90 | HSP90AA1 (0.81) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL1984746 | 0.90 | HSP90AA1 (0.81) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL1989142 | 0.89 | HSP90AA1 (0.81) | HSP90AA1HSP90AB1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928875-B1 | 2-amino-7,8-dihydro-6H-pyrido(4,3-d)pyrimidin-5-ones, process for their preparation and pharmaceutical compositions containing the same | NOVARTIS AG (CH) | 2011-06-29 | — | — | EP | claimed |
| US-7671059-B2 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | NOVARTIS AG (CH) | 2010-03-02 | — | — | US | claimed |
| EP-1928875-B1 | 2-amino-7,8-dihydro-6H-pyrido(4,3-d)pyrimidin-5-ones, process for their preparation and pharmaceutical compositions containing the same | NOVARTIS AG (CH) | 2011-06-29 | — | — | EP | disclosed |
| EP-1928875-B1 | 2-amino-7,8-dihydro-6H-pyrido(4,3-d)pyrimidin-5-ones, process for their preparation and pharmaceutical compositions containing the same | NOVARTIS AG (CH) | 2011-06-29 | — | — | EP | disclosed |
| US-7671059-B2 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | NOVARTIS AG (CH) | 2010-03-02 | — | — | US | disclosed |
| US-7671059-B2 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | NOVARTIS AG (CH) | 2010-03-02 | — | — | US | disclosed |
| US-7671059-B2 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | NOVARTIS AG (CH) | 2010-03-02 | — | — | US | disclosed |
| US-20100004237-A1 | 2-Amino-7,8-dihydro-6H-pyrido[4,3-D]pyrimidin-5-ones | MACHAKEWSKI TIMOTHY D | 2010-01-07 | — | — | US | disclosed |
| US-20100004237-A1 | 2-Amino-7,8-dihydro-6H-pyrido[4,3-D]pyrimidin-5-ones | MACHAKEWSKI TIMOTHY D | 2010-01-07 | — | — | US | disclosed |
| US-20100004237-A1 | 2-Amino-7,8-dihydro-6H-pyrido[4,3-D]pyrimidin-5-ones | MACHAKEWSKI TIMOTHY D | 2010-01-07 | — | — | US | disclosed |
| US-20070123546-A1 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | CHIRON CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20070123546-A1 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | CHIRON CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20070123546-A1 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | CHIRON CORPORATION | 2007-05-31 | — | — | US | disclosed |
| WO-2007041362-A1 | 2-AMINO-7,8-DIHYDRO-6H-PYRIDO[4,3-D] PYRIMIDIN-5-ONES | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123546-A1 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | TYMP, TPMT, TYMS | HSP90AA1 4308/4885HSP90AB1 4303/4885TRAP1 2243/4885 |
| US-20100004237-A1 | 2-Amino-7,8-dihydro-6H-pyrido[4,3-D]pyrimidin-5-ones | TYMP, TPMT, TYMS | HSP90AA1 4308/4885HSP90AB1 4303/4885TRAP1 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.